Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
9 studies found for:    phasebio
Show Display Options
Rank Status Study
1 Recruiting Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)
Condition: Heart Failure
Interventions: Drug: PB1046 Injection;   Drug: Placebo Injection
2 Completed Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: PE0139 Injection;   Drug: Placebo Injection
3 Completed Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: Placebo Single IV (Intravenous) Infusion;   Drug: Experimental: Single IV Infusion Vasomera (PB1046)
4 Completed Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus (T2DM)
Interventions: Drug: PE0139 Injection;   Drug: Placebo
5 Completed Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: 50 mg PB1023;   Drug: 70 mg PB1023;   Drug: 100 mg PB1023;   Drug: Placebo (0.9% Sodium Chloride);   Drug: Victoza®;   Other: Diet and Exercise;   Drug: Metformin;   Drug: Sulfonylurea;   Drug: Metformin and Sulfonylurea
6 Completed Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: Vasomera (PB1046);   Drug: 0.9% Sodium Chloride
7 Completed Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: PB1023 Injection
8 Completed Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Single Dose PB1023
9 Completed Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl);   Drug: Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)

Study has passed its completion date and status has not been verified in more than two years.